A detailed history of Harbour Investments, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbour Investments, Inc. holds 461 shares of REGN stock, worth $530,237. This represents 0.02% of its overall portfolio holdings.

Number of Shares
461
Previous 553 16.64%
Holding current value
$530,237
Previous $532,000 9.02%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

SELL
$883.2 - $1071.19 $81,254 - $98,549
-92 Reduced 16.64%
461 $484,000
Q1 2024

Jul 22, 2024

BUY
$902.69 - $993.35 $146,235 - $160,922
162 Added 41.43%
553 $532,000
Q4 2023

Feb 16, 2024

BUY
$775.18 - $881.7 $5,426 - $6,171
7 Added 1.82%
391 $343,000
Q3 2023

Nov 15, 2023

SELL
$692.45 - $844.37 $49,856 - $60,794
-72 Reduced 15.79%
384 $316,000
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $44,101 - $52,312
63 Added 16.03%
456 $327,000
Q1 2023

May 15, 2023

SELL
$680.49 - $826.97 $2,041 - $2,480
-3 Reduced 0.76%
393 $322,000
Q4 2022

Feb 15, 2023

BUY
$705.89 - $766.39 $4,941 - $5,364
7 Added 1.8%
396 $285,000
Q2 2022

Aug 15, 2022

SELL
$548.35 - $738.84 $8,773 - $11,821
-16 Reduced 3.95%
389 $230,000
Q4 2021

Feb 16, 2022

BUY
$543.48 - $670.97 $25,000 - $30,864
46 Added 12.81%
405 $256,000
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $2,870 - $3,404
-5 Reduced 1.37%
359 $217,000
Q2 2021

Aug 16, 2021

SELL
$472.8 - $558.54 $25,531 - $30,161
-54 Reduced 12.92%
364 $203,000
Q1 2021

Aug 17, 2021

BUY
$446.73 - $548.2 $186,286 - $228,599
417 Added 41700.0%
418 $198,000
Q1 2021

May 12, 2021

BUY
$446.73 - $548.2 $446 - $548
1 New
1 $1,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $123B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.